NCT04086472View on ClinicalTrials.gov

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

March 22, 2020

Study Completion Date

August 14, 2020

Conditions
Respiratory Syncytial Viruses
Interventions
BIOLOGICAL

Clesrovimab

Single dose of clesrovimab administered via IV infusion.

OTHER

Placebo

Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.

BIOLOGICAL

RSV-A Memphis 37b

Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Trial Locations (1)

E1 2AX

HVIVO Services Ltd ( Site 0001), London

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04086472 - Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) | Biotech Hunter | Biotech Hunter